Skip to main content
SpringerLink
Log in

The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator

  • Commentary
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

The Original Article was published on 18 November 2010

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Zaniolo, O., Iannazzo, S., Pradelli, L., Miravitlles, M.: Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy. Eur J Health Econ 13(1), 71–80 (2012). doi:10.1007/s10198-010-0285-8

    Article  CAS  PubMed  Google Scholar 

  2. Neyt, M., Van Brabandt, H.: The importance of the comparator in economic evaluations: working on the efficiency frontier. PharmacoEconomics 29(11), 913–916 (2011). doi:10.2165/11595260-000000000-00000

    Article  PubMed  Google Scholar 

  3. Global Initiative for Chronic Obstructive Lung Disease (GOLD): Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2011). http://www.goldcopd.org/

  4. Neyt, M., Van den Bruel, A., Gailly, J., Thiry, N., Devriese, S.: Tiotropium in the treatment of chronic obstructive pulmonary disease: health technology assessment. In: Health Technology Assessment. KCE reports 108C. Belgian Health Care Knowledge Centre (KCE), Brussels (2009)

  5. Van den Bruel, A., Gailly, J., Neyt, M.: Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med 10, 50 (2010). doi:10.1186/1471-2466-10-50

    PubMed  Google Scholar 

  6. Brusasco, V., Hodder, R., Miravitlles, M., Korducki, L., Towse, L., Kesten, S.: Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 58(5), 399–404 (2003)

    Article  CAS  PubMed  Google Scholar 

  7. Briggs Jr, D.D., Covelli, H., Lapidus, R., Bhattycharya, S., Kesten, S., Cassino, C.: Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm. Pharmacol. Ther. 18(6), 397–404 (2005)

    Article  CAS  PubMed  Google Scholar 

  8. National Institute for Health and Disability Insurance: Individual revision of the pharmaceutical product Spiriva. Rijksinstituut voor Ziekte- en Invaliditeitsverzekering (RIZIV), Brussels (2007)

Download references

Author information

Authors and Affiliations

  1. Belgian Health Care Knowledge Centre (KCE), Kruidtuinlaan 55, 1000, Brussels, Belgium

    Mattias Neyt

  2. Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

    Ann Van Den Bruel

Authors
  1. Mattias Neyt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ann Van Den Bruel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mattias Neyt.

Additional information

This comment refers to the article available at doi:10.1007/s10198-010-0285-8.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Neyt, M., Van Den Bruel, A. The cost-effectiveness of tiotropium for the treatment of chronic obstructive pulmonary disease (COPD): the importance of the comparator. Eur J Health Econ 13, 379–380 (2012). https://doi.org/10.1007/s10198-012-0392-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-012-0392-9

Keywords

Search

Navigation